Krystal Biotech possesses an advanced, proprietary gene therapy pipeline leveraging its unique, non-replicating engineered viral vector platform designed to deliver treatments repeatedly without triggering adverse systemic immune responses. Its anchor commercial asset is VYJUVEK, approved for dystrophic epidermolysis bullosa. Beyond this, the pipeline includes developmental candidates targeting severe ophthalmic, respiratory, and oncological conditions. Notable programs include KB803, which is undergoing clinical evaluation for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa patients through an advanced decentralized trial design, and KB801, currently being studied in registrational trials for neurotrophic keratitis. Additionally, the company is actively expanding its platform utility into pulmonary disorders like cystic fibrosis and various localized tumor types, aiming to transition from a single-product rare disease specialist into a diversified multi-product genetic medicines powerhouse.